gaboxadol gaboxadol gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (thip), is a conformationally constrained derivative of the alkaloid muscimol that was first synthesized in 1977 by the danish chemist povl krogsgaard-larsen. in the early 1980s gaboxadol was the subject of a series of pilot studies that tested its efficacy as an analgesic and anxiolytic, as well as a treatment for tardive dyskinesia, huntington's disease, alzheimer's disease, and spasticity. it was not until 1996 that researchers attempted to harness gaboxadol's frequently reported sedative "adverse effect" for the treatment of insomnia, resulting in a series of clinical trials sponsored by lundbeck and merck. in march, 2007, merck and lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. it acts on the gaba system, but in a different way from benzodiazepines, z-drugs, and barbiturates. lundbeck states that gaboxadol also increases deep sleep (stage 4). unlike benzodiazepines, thip does not demonstrate reinforcement in mice or baboons despite activation of dopaminergic neurons in the ventral tegmental area. gaboxadolclinical dataatc codenoneidentifiers iupac name 4,5,6,7-tetrahydroisoxazolopyridin-3(2h)-one cas number64603-91-4 ypubchem cid3448iuphar/bps4322chemspider3330 yuniik1m5rvl18skeggd04282 ychemblchembl312443 ycomptox dashboard (epa)dtxsid0045206 echa infocard100.059.039 chemical and physical dataformulac6h8n2o2molar mass140.142 g·mol−13d model (jsmol)interactive image smiles o=c1/c2=c(\on1)cncc2 inchi inchi=1s/c6h8n2o2/c9-6-4-1-2-7-3-5(4)10-8-6/h7h,1-3h2,(h,8,9) ykey:zxrvkcblgjocee-uhfffaoysa-n y ny (what is this?) (verify) in 2015, lundbeck sold its rights to the molecule to ovid therapeutics, whose plan is to develop it for fxs and angelman syndrome. it is known internally in ovid as ov101.